FBT-002

– Fabentech received approval from French Health Authority (ANSM) to launch a phase 1 clinical trial to evaluate the safety and pharmacokinetics of FBT-002, a life-saving therapeutic against a plant-based toxin, at ascending dose levels. – The trial enrols 24 healthy volunteers in France, with a dose escalation design. – Healthy volunteers received the anticipated therapeutic dose, and the study safety committee confirmed that FBT-002 is well tolerated at this dosage.